Mydecine Innovations Group, Inc. is a biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2014-08-18. The firm is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The firm conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The firm has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The firm is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). The company utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.